Fig. 1: Clinical outcomes of first-line treatment options in Cohorts 1 and 2.
From: Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma
Kaplan–Meier analysis of A overall survival (OS) in Cohort 1, B OS in Cohort 2, and C real-world progression-free survival (rwPFS) in Cohort 1, comparing patients with pulmonary large cell neuroendocrine carcinoma treated with chemotherapy (n = 119 for Cohort 1, n = 47 for Cohort 2), chemoimmunotherapy (n = 81 for Cohort 1, n = 99 for Cohort 2), or immunotherapy (n = 14 for Cohort 1, n = 12 for Cohort 2). Survival distributions were compared using a two-sided log-rank test. D Tornado plot depicting treatment-related adverse events for patients treated with any first-line systemic therapy in Cohort 1 (n = 216). Any grade (right) and ≥grade 3 (left). HR hazard ratio, ref reference. Statistical significance is defined as p < 0.05.
